Optimization of Novel Indazoles as Highly Potent and Selective Inhibitors of Phosphoinositide 3-Kinase δ for the Treatment of Respiratory Disease

Journal of Medicinal Chemistry

Volumn 58, Issue 18, 2015, Pages 7381-7399

  Down, Kenneth ^a   Amour, Augustin ^a   Baldwin, Ian R ^a   Cooper, Anthony W J ^a   Deakin, Angela M ^a   Felton, Leigh M ^a   Guntrip, Stephen B ^a,b   Hardy, Charlotte ^a   Harrison, Zoë A ^a   Jones, Katherine L ^a   Jones, Paul ^a   Keeling, Suzanne E ^a   Le, Joelle ^a   Livia, Stefano ^a   Lucas, Fiona ^a   Lunniss, Christopher J ^a   Parr, Nigel J ^a   Robinson, Ed ^a   Rowland, Paul ^a   Smith, Sarah ^a   Thomas, Daniel A ^a   Vitulli, Giovanni ^a   Washio, Yoshiaki ^a   Hamblin, J Nicole ^a   more..

^a GLAXOSMITHKLINE   (United Kingdom)

^b Argenta Discovery Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

6 CHLORO 4 [5 [(2,6 DIMETHYL 4 MORPHOLINYL)METHYL] 1,3 OXAZOL 2 YL] 1 (PHENYLSULFONYL) 1H INDAZOLE; INDAZOLE DERIVATIVE; N [5 [4 [5 [(2,6 DIMETHYL 4 MORPHOLINYL)METHYL] 1,3 OXAZOL 2 YL] 1H INDAZOL 6 YL] 2 (METHYLOXY)3 PYRIDINYL]METHANESULFONAMIDE; PHOSPHATIDYLINOSITOL 3 KINASE GAMMA; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; UNCLASSIFIED DRUG; GSK2269557; GSK2292767; ISOENZYME; OVALBUMIN; OXAZOLE DERIVATIVE; PHOSPHATIDYLINOSITOL 3 KINASE; SULFONAMIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BROWN NORWAY RAT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG POTENCY; DRUG SCREENING; DRUG SELECTIVITY; FEMALE; HUMAN; HUMAN CELL; MALE; NONHUMAN; RABBIT; RAT; RESPIRATORY TRACT DISEASE; STRUCTURE ACTIVITY RELATION; ANIMAL; ANTAGONISTS AND INHIBITORS; ASTHMA; CHEMISTRY; IMMUNOLOGY; INHALATIONAL DRUG ADMINISTRATION; METABOLISM; MICROSOME; MOLECULAR DOCKING; PNEUMONIA; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY TRACT DISEASES; SPRAGUE DAWLEY RAT; STEREOISOMERISM; TH2 CELL;

ADMINISTRATION, INHALATION; ANIMALS; ASTHMA; FEMALE; HUMANS; INDAZOLES; ISOENZYMES; MALE; MICROSOMES; MOLECULAR DOCKING SIMULATION; OVALBUMIN; OXAZOLES; PHOSPHATIDYLINOSITOL 3-KINASES; PNEUMONIA; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RABBITS; RATS; RATS, SPRAGUE-DAWLEY; RESPIRATORY TRACT DISEASES; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES; TH2 CELLS;

EID: 84942279293     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.5b00767     Document Type: Article

References (27)

1. Cantley, L. C. The phosphoinositide 3-kinase pathway Science 2002, 296, 1655-1657 10.1126/science.296.5573.1655
2. Vanhaesebroeck, B.; Guillermet-Guibert, J.; Graupera, M.; Bilanges, B. The emerging mechanisms of isoform-specific PI3K signalling Nat. Rev. Mol. Cell Biol. 2010, 11, 329-341 10.1038/nrm2882
3. Foster, J. G.; Blunt, M. D.; Carter, E.; Ward, S. G. Inhibition of PI3K signaling spurs new therapeutic opportunities in inflammatory/autoimmune diseases and hematological malignancies Pharmacol. Rev. 2012, 64, 1027-1054 10.1124/pr.110.004051
4. Engelman, J. A.; Luo, J.; Cantley, L. C. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism Nat. Rev. Genet. 2006, 7, 606-619 10.1038/nrg1879
5. McNamara, C. R.; Degterev, A. Small-molecule inhibitors of the PI3K signaling network Future Med. Chem. 2011, 3, 549-565 10.4155/fmc.11.12
6. Rowan, W. C.; Smith, J. L.; Affleck, K.; Amour, A. Targeting phosphoinositide 3-kinase δ for allergic asthma Biochem. Soc. Trans. 2012, 40, 240-245 10.1042/BST20110665
7. Sriskantharajah, S.; Hamblin, N.; Worsley, S.; Calver, A. R.; Hessel, E. M.; Amour, A. Targeting phosphoinositide 3-kinase δ for the treatment of respiratory diseases Ann. N. Y. Acad. Sci. 2013, 1280, 35-39 10.1111/nyas.12039
8. Ball, J.; Archer, S.; Ward, S. PI3K inhibitors as potential therapeutics for autoimmune disease Drug Discovery Today 2014, 19, 1195-1199 10.1016/j.drudis.2014.04.002
9. Vanhaesebroeck, B.; Ali, K.; Bilancio, A.; Geering, B.; Foukas, L. C. Signalling by PI3K isoforms: insights from gene-targeted mice Trends Biochem. Sci. 2005, 30, 194-204 10.1016/j.tibs.2005.02.008
10. Rückle, T.; Schwarz, M. K.; Rommel, C. PI3Kγ inhibition: towards an 'aspirin of the 21st century'? Nat. Rev. Drug Discovery 2006, 5, 903-918 10.1038/nrd2145
11. Dienstmann, R.; Rodon, J.; Serra, V.; Tabernero, J. Picking the point of inhibition: A comparative review of PI3K/AKT/mTOR pathway inhibitors Mol. Cancer Ther. 2014, 13, 1021-1031 10.1158/1535-7163.MCT-13-0639
12. Bamborough, P.; Christopher, J. A.; Cutler, G. J.; Dickson, M. C.; Mellor, G. W.; Morey, J. V.; Patel, C. B.; Shewchuk, L. M. 5-(1H-Benzimidazol-1-yl)-3-alkoxy-2-thiophenecarbonitriles as potent, selective, inhibitors of IKK-ε kinase Bioorg. Med. Chem. Lett. 2006, 16, 6236-6240 10.1016/j.bmcl.2006.09.018
13. Borgström, L.; Olsson, B.; Thorsson, L. Degree of throat deposition can explain the variability in lung deposition of inhaled drugs J. Aerosol Med. 2006, 19, 473-483 10.1089/jam.2006.19.473
14. Bhattachar, S. N.; Wesley, J. A.; Seadeek, C. Evaluation of the chemiluminescent nitrogen detector for solubility determinations to support drug discovery J. Pharm. Biomed. Anal. 2006, 41, 152-157 10.1016/j.jpba.2005.11.009
15. ClogP, version 4.0; Biobyte Corp.: Claremont, CA; http://www.biobyte.com/index.html.
16. Sutherlin, D. P.; Baker, S.; Bisconte, A.; Blaney, P. M.; Brown, A.; Chan, B. K.; Chantry, D.; Castanedo, G.; DePledge, P.; Goldsmith, P.; Goldstein, D. M.; Hancox, T.; Kaur, J.; Knowles, D.; Kondru, R.; Lesnick, J.; Lucas, M. C.; Lewis, C.; Murray, J.; Nadin, A. J.; Nonomiya, J.; Pang, J.; Pegg, N.; Price, S.; Reif, K.; Safina, B. S.; Salphati, L.; Staben, S.; Seward, E. M.; Shuttleworth, S.; Sohal, S.; Sweeney, Z. K.; Ultsch, M.; Waszkowycz, B.; Wei, B. Potent and selective inhibitors of PI3Kδ: Obtaining isoform selectivity from the affinity pocket and tryptophan shelf Bioorg. Med. Chem. Lett. 2012, 22, 4296-4302 10.1016/j.bmcl.2012.05.027
17. BHX database: Toward a better understanding of hydrogen-bond basicity for medicinal chemists J. Med. Chem. 2009, 52, 4073-4086 10.1021/jm801331y
18. Peterson, L. A. Reactive metabolites in the biotransformation of molecules containing a furan ring Chem. Res. Toxicol. 2013, 26, 6-25 10.1021/tx3003824
19. Gribble, F. M.; Loussouarn, G.; Tucker, S. J.; Zhao, C.; Nichols, C. G.; Ashcroft, F. M. A novel method for measurement of submembrane ATP concentration J. Biol. Chem. 2000, 275, 30046-30049 10.1074/jbc.M001010200
20. EMD Millipore Corporation. http://www.merckmillipore.com.
21. 2 receptor agonist with rapid onset of action ACS Med. Chem. Lett. 2014, 5, 416-421 10.1021/ml4005232
22. Aronov, A. M. Common pharmacophores for uncharged human ether-a-go-go-related gene (hERG) blockers J. Med. Chem. 2006, 49, 6917-6921 10.1021/jm060500o
23. Knight, S. D.; Adams, N. D.; Burgess, J. L.; Chaudhari, A. M.; Darcy, M. G.; Donatelli, C. A.; Luengo, J. I.; Newlander, K. A.; Parrish, C. A.; Ridgers, L. H.; Sarpong, M. A.; Schmidt, S. J.; Van Aller, G. S.; Carson, J. D.; Diamond, M. A.; Elkins, P. A.; Gardiner, C. M.; Garver, E.; Gilbert, S. A.; Gontarek, R. R.; Jackson, J. R.; Kershner, K. L.; Luo, L.; Raha, K.; Sherk, C. S.; Sung, C.-M.; Sutton, D.; Tummino, P. J.; Wegrzyn, R. J.; Auger, K. R.; Dhanak, D. Discovery of GSK2126458, a highly potent inhibitor of PI3K and the mammalian target of rapamycin ACS Med. Chem. Lett. 2010, 1, 39-43 10.1021/ml900028r
24. Berndt, A.; Miller, S.; Williams, O.; Le, D. D.; Houseman, B. T.; Pacold, J. I.; Gorrec, F.; Hon, W.-C.; Ren, P.; Liu, Y.; Rommel, C.; Gaillard, P.; Rückle, T.; Schwarz, M. K.; Shokat, K. M.; Shaw, J. P.; Williams, R. L. The p110δ structure: mechanisms for selectivity and potency of new PI(3)K inhibitors Nat. Chem. Biol. 2010, 6, 117-124 10.1038/nchembio.293
25. Hopkins, A. L.; Groom, C. R.; Alex, A. Ligand efficiency: a useful metric for lead selection Drug Discovery Today 2004, 9, 430-431 10.1016/S1359-6446(04)03069-7
26. Rice, L. V.; Bax, H. J.; Russell, L. J.; Barrett, V. J.; Walton, S. E.; Deakin, A. M.; Thomson, S. A.; Lucas, F.; Solari, R.; House, D.; Begg, M. Characterization of selective calcium-release activated calcium channel blockers in mast cells and T-cells from human, rat, mouse and guinea-pig preparations Eur. J. Pharmacol. 2013, 704, 49-57 10.1016/j.ejphar.2013.02.022
27. Liu, T.; Brown, B. S.; Wu, Y.; Antzelevitch, C.; Kowey, P. R.; Yan, G. X. Blinded validation of the isolated arterially perfused rabbit ventricular wedge in preclinical assessment of drug-induced proarrhythmias Heart Rhythm 2006, 3, 948-956 10.1016/j.hrthm.2006.04.021